Autopsy report · NCT00461266

ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Slow recruitment”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 4
Sponsor: Hoffmann-La Roche
Sponsor type: Industry
Conditions: HIV Infections
Interventions: enfuvirtide [Fuzeon]; Antiretroviral therapy
Participants: 0
Sites: 7
Countries: Australia

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.